RxDoctor Payments Data

Michael Liguori, MD

Internal Medicine · New York, NYNPI 1043367204

Payments from drug & device makers

$4,602in general payments, 2019–2025

Across 262 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$1K
  • Merck$372
  • AstraZeneca$288
  • GSK$213
  • Pfizer$166
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,602 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$136,239
Medicare patients
172
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi36$150,219
BiktarvyBictegrav/Emtricit/Tenofov Ala15$88,014
DescovyEmtricitabine/Tenofov Alafenam38$87,936
TivicayDolutegravir Sodium39$85,594
JulucaDolutegravir/Rilpivirine15$51,987
JardianceEmpagliflozin27$36,614
IsentressRaltegravir Potassium13$29,596
XareltoRivaroxaban15$22,658
EliquisApixaban16$22,626
IntelenceEtravirine13$19,550
NexletolBempedoic Acid12$14,400
TrulicityDulaglutide13$12,259
Atorvastatin Calcium185$1,959
Duloxetine Hcl32$1,763
Rosuvastatin Calcium46$1,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Tivicay, Juluca$1,342$287,80190 claims
GileadBiktarvy, Descovy$1,167$175,95053 claims
MerckIsentress$372$29,59613 claims
Johnson & JohnsonXarelto$150$22,65815 claims
PfizerEliquis$166$22,62616 claims
Esperion Therapeutics, Inc.Nexletol$95$14,40012 claims
Lilly USA, LLCTrulicity$103$12,25913 claims
Almatica Pharma LLCSertraline Hcl$14$50338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →